Axon (AXON) CRO Cameron Brooks sells 1,221 shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

Axon Enterprise's Chief Revenue Officer, Cameron Brooks, reported an open-market sale of 1,221 shares of common stock. The shares were sold at an average price of $565.51 per share. After this transaction, Brooks directly holds about 57,545 shares, so the sale represents a small portion of his overall position. According to a footnote, the trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025, indicating it was scheduled in advance rather than timed opportunistically.

Insights

Equity markets analyst

Routine, pre-planned insider sale of a small share portion.

The Chief Revenue Officer of Axon Enterprise sold 1,221 shares of common stock at $565.51 per share in an open-market transaction. Following the sale, he still directly holds about 57,545 shares, indicating this is a minor trim relative to his position.

A footnote states the transaction was carried out under a Rule 10b5-1 trading plan adopted on December 8, 2025. Such pre-arranged plans automate trades over time, which generally makes the timing less informative about the insider’s current view of the stock. The filing shows no derivative exercises or gifts associated with this trade.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brooks Cameron

(Last) (First) (Middle)

17800 NORTH 85TH STREET

(Street)

SCOTTSDALE AZ 85255

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AXON ENTERPRISE, INC. [ AXON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF REVENUE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		S(1)		1,221	D	$565.51	57,545.39	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 8, 2025.

Remarks:

	/s/ Cameron Brooks by Isaiah Fields, Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Axon (AXON) report for Cameron Brooks?

Axon reported that Chief Revenue Officer Cameron Brooks sold 1,221 shares of common stock. The open-market sale occurred at an average price of $565.51 per share, and was disclosed on a Form 4 insider trading report.

How large is Cameron Brooks’ remaining Axon (AXON) stake after this Form 4 sale?

After selling 1,221 shares, Cameron Brooks directly holds about 57,545 Axon common shares. This indicates the reported transaction represents only a small fraction of his overall disclosed equity position in the company.

Was the Axon (AXON) insider sale made under a Rule 10b5-1 trading plan?

Yes. A footnote explains the transactions were effected under a Rule 10b5-1 trading plan adopted by Cameron Brooks on December 8, 2025, meaning the trade was pre-scheduled rather than decided at the last moment.

What was the sale price for the Axon (AXON) shares in Cameron Brooks’ Form 4?

The 1,221 Axon shares sold by Cameron Brooks were transacted at an average price of $565.51 per share. This price reflects the weighted average of the open-market sale reported in the filing.

Does the Axon (AXON) Form 4 include any option exercises or derivative trades?

No. The Form 4 shows only a non-derivative open-market sale of common stock. The derivative section is empty, and the summary lists zero derivative exercises or other derivative transactions for this reporting period.

How significant is Cameron Brooks’ Axon (AXON) share sale for investors?

The sale of 1,221 shares is small compared with his remaining holdings of about 57,545 shares. Combined with its execution under a pre-arranged Rule 10b5-1 plan, it appears as a routine liquidity event rather than a major position change.